A new publication involving the stable pentadecapeptide BPC-157 appeared on June 1, 2026. The paper, titled "Stable pentadecapeptide therapy counteracts gentamicin-induced nephrotoxicity via nitric oxide-system modulation: evidence from a triple nitric oxide-agent approach in rats," was published in the Journal of Physiology and Pharmacology, an official journal of the Polish Physiological Society. The study is listed under PubMed ID 42533460. BPC-157 remains classified as an unapproved compound used only in research settings. This publication is noted here solely to record its existence and bibliographic details. No specific findings, outcomes, or conclusions from the study are described in the available event data, and none should be assumed. The listing does not indicate efficacy, safety, or therapeutic benefit associated with BPC-157. Readers interested in the full scope of the research, including methodology and results, are encouraged to consult the original article directly through the provided source link. As with all early-stage or preclinical research, findings in animal models do not necessarily translate to human outcomes. For general background on this compound, readers can refer to the compound overview page.
New Publication on BPC-157 and Gentamicin-Induced Nephrotoxicity in Rats
Source: https://pubmed.ncbi.nlm.nih.gov/42533460/